Archive for the ‘Personalized Medicine’ Category

27-01-2012 09:48 From ASH 2011 - K. Stephen Suh, Ph.D., Director of Genomics and Biomarkers Program at the John Theurer Cancer Center at the Hackensack University Medical Center, discusses personalized medicine, genomics and biomarkers. For more information, please visit The John Theurer Cancer Center website at: http://www.humccancer.org

Original post:
Personalized Medicine, Genomics and Biomarkers - Interview with K. Stephen Suh, Ph.D. - Video

31-01-2012 08:03 The drug Kalydeco has been approved to treat patients with one of the mutations that cause cystic fibrosis. FDA's Stephen Spielberg, MD, Ph.D, tells how this targeted treatment represents how personalized medicine will revolutionize health care.

Read more from the original source:
Cystic Fibrosis Drug is Personalized Medicine - Video

Updated: Tue Jan. 31 2012 19:10:38

ctvwinnipeg.ca

The federal health minister says the government would like to move away from "one size fits all" medicine.

An announcement was made in Ottawa on Tuesday that more than $67 million is being invested into cutting edge research to identify markers of disease.

The aim is to get doctors to understand a person's body through their genes, family background and environment, then tailor a treatment just for them.

"With these bio markers, doctors will be able to tailor treatments based on what we know about the patient being treated," said Leona Aglukkaq, Health Minister. "this holds the potential to make many medical treatments more effective."

Some Manitobans feel it's money well spent, like Carey Tarr who has type 1 diabetes. She says she already recieves some treatment personalized for her, but says more can be done for others.

"Someone living with type one diabetes or any type diabetes may also be living with other conditions, " explained Tarr, "So there's a lot of room to look at how their body makeup and different conditions they are living with are affecting others as well."

It's believed personalized approaches will be effective in many areas including cancer.

CancerCare Manitoba says this initiative is a small step in the right direction.

"This is an initiatve that will begin to improve the specificity of our care so we aren't using a shot gun approach as we are sometimes forced to because we have no other way," said Dr. Dhali Dhaliwal, of CancerCare Manitoba.

Dr Dhaliwal says it could take at least five years before patients will see the benifits of this research.

The government says the funding is a research competition supported by three research groups, who have to match the amount of money they receive.

It's not known at this time what diseases the groups will be conducting research on.

-- with a report from CTV's Ina Sidhu

Read the original:
Personalized medicine could soon be reality

Public release date: 31-Jan-2012
[ | E-mail | Share ]

Contact: Adele Blanchard
ablanchard@cihr.gc.ca
613-946-3308
Canadian Institutes of Health Research

This press release is available in French.

Ottawa, Ontario -- The Harper Government today announced an important investment that will help Canadians in getting more effective treatments and make the healthcare system more sustainable through personalized medicine. The announcement was made by the Honourable Leona Aglukkaq, Minister of Health, and the Honourable Gary Goodyear, Minister of State for Science and Technology.

"Our Government is committed to improving the quality of life of Canadians," Minister Aglukkaq said. "The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health care system and even save costs in certain circumstances."

Personalized medicine offers the potential to transform the delivery of healthcare to patients. Healthcare will evolve from a reactive "one-size-fits-all" system towards a system of predictive, preventive, and precision care. Areas in which personalized approaches are particularly promising include oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer's disease. In all of these fields, and others, a personalized molecular medicine approach is expected to lead to better health outcomes, improved treatments, and reduction in toxicity due to variable or adverse drug responses. For example, cancer patients would be screened to identify those for whom chemotherapy would be ineffective. In addition to saving on the costs of expensive drug treatments, this personalized treatment would prevent a great deal of suffering, while identifying and initiating earlier treatments that would be more effective.

"I applaud Genome Canada and the CIHR for their leadership in supporting research in personalized medicine," said Minister Goodyear. "Innovative approaches like these lead to significant health benefits, enhance our knowledge within the medical arena and can be commercialized to help so many others worldwide."

###

Genome Canada is leading the landmark research competition, with significant collaboration from the Canadian Institutes of Health Research (CIHR) and the Cancer Stem Cell Consortium (CSCC). To qualify for funding, researchers must obtain matching funding that at is least equal to that provided through the competition. Matching funding is typically derived from provincial, academic, private sector or international sources.

Fact Sheet

Further information:

Cailin Rodgers
Office of the Honourable Leona Aglukkaq
Federal Minister of Health
613-957-0200

Stephanie Thomas
Special Assistant (Communications)
Office of the Honourable Gary Goodyear
Minister of State (Science and Technology)
613-960-7728

David Coulombe
Media Relations
Canadian Institutes of Health Research
613-941-4563

Marlene Orton
Director, Media Relations
Genome Canada
613-751-4460 x119
BlackBerry: 613-295-1476

The Canadian Institutes of Health Research (CIHR) is the Government of Canada's health research investment agency. CIHR's mission is to create new scientific knowledge and to enable its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 14,100 health researchers and trainees across Canada. http://www.cihr-irsc.gc.ca

Genome Canada is a non-profit corporation employing an innovative business model based on funding and managing large-scale, multidisciplinary, internationally peer-reviewed genomics research projects in areas such as agriculture, forestry, fisheries, the environment and human health. For more information, visit http://www.genomecanada.ca

The Cancer Stem Cell Consortium is a not-for-profit corporation that was incorporated in 2007 to coordinate an international strategy for cancer stem cell research and related translational activities. For more information, visit http://www.cancerstemcellconsortium.ca

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Go here to read the rest:
Harper government invests in personalized medicine

NEW YORK & PARIS--(BUSINESS WIRE)-- Bionest Partners, a premier strategy and management consulting firm for life science industries, and a recognized leader in personalized medicine strategy consulting, announces the publication of an article in a supplement to the Dec. 23, 2011 issue of Science. The article, co-authored by Dr. Edward Abrahams, President of the Personalized Medicine Coalition (PMC), focuses on how best to optimize decision-making for personalized medicine research and development (R&D) and commercialization strategies.

The adoption of personalized medicine strategies could bring great benefits to patients, medical service providers, payers, and the manufacturers of personalized medicine products (e.g., pharmaceutical and diagnostic companies). The article discusses the complexities and uncertainties that personalized medicine introduces for pharmaceutical and diagnostic companies, and how they can address those challenges from commercial, operational, scientific and clinical perspectives. The authors highlight the use of quantitative modeling and decision-analysis tools. In addition, they emphasize the importance of the “soft art” of communication and consensus building within the organization.

Dr. Sean X. Hu, Head of Bionest USA and Managing Director, North America, and lead author, points out that “the key to success lies in the mastery of both the science and the art of personalized medicine strategy decision-making. This article summarizes the combined approach we employ to help companies make the right decisions in a still emerging field.”

Dr. Edward Abrahams adds: “The field of personalized medicine has come a long way over the last decade, to the point that it is now embedded in nearly every major pharmaceutical and diagnostic company research or product portfolio. Nevertheless, companies are struggling with how to navigate a still uncertain regulatory and payer environment, and formulate effective market strategies. The tools and approaches we refer to in this article are an important step toward providing a ‘GPS’ for making the right strategic decisions.”

Bionest is sponsoring the upcoming PMC reception at the InterContinental San Francisco on February 22, 2012, concurrent with the Molecular Medicine TriConference. For further discussions with Drs. Hu and Abrahams on personalized medicine strategies, either at the PMC reception or at another time, please contact Dr. Rachel Laing (rlaing@bionest.com).

Bionest has become a powerhouse in personalized medicine strategy consulting, experienced in a broad spectrum of project types, from the corporate level (personalized medicine business models, commercialization capability building, R&D and commercialization business processes, and organizational structure) to development and commercialization strategies for individual drug assets and companion diagnostics.

In addition, Bionest has been driving thought leadership on personalized medicine, with many articles published or in development on the strategic, commercial and technical aspects of personalized medicine.

For more details, please visit http://www.bionest.com, (navigate to section Strategic/Strategic Practice/Personalized Medicine Strategies).

About Bionest Partners

Bionest Partners provides advisory and management services exclusively for the life science industries, and helps pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and medical device companies and their shareholders to maximize the value of their assets and investments. The company, founded in 2003, has offices in Paris and New York. Its broad customer base includes more than 100 clients ranging from large established companies to biotech start-ups and private equity firms, such as Pfizer, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, AstraZeneca, Johnson & Johnson, Bayer, BiogenIdec, Millennium, MedImmune, Idenix, ProStrakan, Stallergenes, Innate Pharma, Genfit, Jubilant, Sequenom, Axa Private Equity, Blackstone, Candover. The company focuses on providing actionable strategies through its expertise in management consulting, including corporate, franchise, portfolio and product commercialization, organizational and marketing strategies, due diligence, surrogate management, as well as entry into European and US markets. Bionest has a global network of consultants and associate members deployed to address specific client assignments and geographical markets in the Americas, Europe, and Asia Pacific.

About the Personalized Medicine Coalition

The Personalized Medicine Coalition (PMC), representing scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information on the Personalized Medicine Coalition, please visit http://www.PersonalizedMedicineCoalition.org.

Continued here:
Bionest and PMC Address Optimization of Personalized Medicine Strategies

The federal government is pledging up to $67.5 million for research into "personalized medicine," which tailors treatment to a patient's genetics and environment.

The funds will flow through Genome Canada, the Cancer Stem Cell Consortium and the Canadian Institutes of Health Research, the federal government's health research agency.

Federal Health Minister Leona Aglukkaq and Minister of State for Science Gary Goodyear made the announcement at the University of Ottawa's health campus Tuesday.

The field of personalized medicine is touted as having the potential to transform the way patients are treated. It looks at the genetic makeup of a person, the patient's environment and the exact course of a particular disease so that an appropriate and effective treatment can be tailored for that individual.

The idea is to move from a one-size-fits-all approach to one that is designed for a specific person and relies on the genetic signatures, or biomarkers, of both the patient and the disease.

Proponents of personalized medicine say it is likely to change the way drugs are developed, how medicines are prescribed and generally how illnesses are managed. They say it will shift the focus in health care from reaction to prevention, improve health outcomes, make drugs safer and mean fewer adverse drug reactions, and reduce costs to health-care systems.

"The potential to understand a person's genetic makeup and the specific character of their illness in order to best determine their treatment will significantly improve the quality of life for patients and their families and may show us the way to an improved health-care system and even save costs in certain circumstances," Aglukkaq said in a news release.

Research projects could last four years

The sequencing of the human genome paved the way for personalized medicine and there have been calls for more research funding so that the discoveries in laboratories can be translated further into the medical field so they will benefit patients more.

Identifying a person's genetic profile, for example, could then indicate a susceptibility to a certain disease, if the biomarkers of that disease have also been discovered. If people know they are genetically at risk of an illness they can take actions to prevent it, and their health-care providers can monitor for it.

Cancer patients could be pre-screened to determine if chemotherapy would work for them, which could not only save a lot of money on expensive treatments but also prevent pain and suffering for patients.

Genome Canada is leading the research initiative, in collaboration with Cancer Stem Cell Consortium and CIHR which on Tuesday launched its Personalized Medicine Signature Initiative. CIHR is committing up to $22.5 million to the large-scale initiative with the other two partners, but it will be providing more funding for other projects under its personalized medicine program.

The research projects are aiming to bring together biomedical, clinical, population health, health economics, ethics and policy researchers to identify areas that are best suited to personalized medicine.

Oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease are all considered to be areas that hold promise for personalized medicine.

Funding will also go to projects that are aimed at developing more evidence-based and cost-effective approaches to health care.

Researchers can get up to four years of funding, but 50 per cent of their requested funding must be matched from another source, such as a provincial government or from the academic or private sectors.

Genome Canada, CIHR and the cancer consortium will invest a maximum of $5 million in each individual project.

The successful applicants for the $67.5 million worth of funding won't be announced until December.

Visit link:
'Personalized medicine' gets $67.5M research boost

ANN ARBOR — Everist Genomics announced Friday that its
executive vice chairman, Alex Charlton, will speak about its
breakthrough CardioDefender Device at the Wearable Technologies
Conference Monday in Munich, Germany.

Smartphone healthcare applications are graduating from novelty
items to mainstream medicine, helping physicians to save lives
and reduce the cost of care.

Everist Genomics, a rapidly growing personalized medicine
company, is successfully integrating smartphone and tablet
computer technology with innovative, medically important
diagnostics and prognostics in the areas of cardiovascular
disease, diabetes and cancer.

Everist Genomics’ CardioDefender is the world’s first
FDA-approved and CE mark-registered smartphone ECG system to
provide physicians and patients with hospital-quality heart
rhythm monitoring outside of the hospital setting.

CardioDefender incorporates several unique capabilities
enabling physicians to diagnose and treat potentially
life-threatening heart arrhythmias that might otherwise be
missed.

CardioDefender is the first system to deliver mobile,
real-time, beat-by-beat, and quantitative heart monitoring and
automated reporting by combining patented analytical smartphone
software with a Wi-Fi device and electrodes.

“The essence of personalized medicine is to diagnose a problem
before there are noticeable symptoms,” Charlton said.
“Physicians who diagnose and treat heart arrhythmias have been
hampered for many years by legacy technology, such as hospital
based ECG systems which confine patients to the high-cost
hospital setting and Holter monitors which do not provide
the comprehensive monitoring needed to detect potentially life
threatening arrhythmias. For the first time, CardioDefender
enables smartphone-based hospital-quality ECG monitoring of
patients 24 hours per day, seven days per week.”

The company’s recently announced commercialization plans of
CardioDefender coincide with reports from various industry
sources projecting significant growth in remote patient
monitoring. According to analyst firm Berg Insight, for
example, around 2.2 million patients worldwide were using home
monitoring service based on equipment with integrated
connectivity at the end of 2011 — cardiac arrhythmia was cited
as one of the most common conditions monitored by these
technologies.

Following FDA approval and European CE Mark registration last
year, CardioDefender has already been deployed at more
than 150 medical facilities in the United States for
post-approval commercial evaluation. Between January and
October of 2011, the number of patient days of heart rhythm
monitoring performed with CardioDefender grew from fewer than
5,000 to more than 18,000 patient days per month. Since the
system was introduced, Everist Genomics has received inquiries
about the product from more than 32 countries, including China,
India and the United States.

Everist Genomics launched its first product last year with the
introduction of OncoDefender-CRC, a prognostic test for
predicting the risk of disease recurrence for early stage
colorectal cancer patients. The company expanded its pipeline
with the creation of a new franchise of diagnostic and
prognostic tests aimed at melding personalized medicine with
mobile health platforms.

In addition to the CardioDefender diagnostic system,
Everist Genomics recently announced development of
AngioDefender, the world’s first tablet computer device capable
of accurately diagnosing atherosclerosis in asymptomatic
patients. The company is developing mobile applications for the
AngioDefender system to extend physician access to vital
patient information and provide clinical support for treatment
planning. The company plans to launch the AngioDefender system
in February 2012.

More at http://www.everistgenomics.com.

Continue reading here:
Smartphone Tech Meets Personalized Medicine: Everist CardioDefender

26-01-2012 02:43 Genome British Columbia Winter Symposium 2012 - Personalized Medicine Q

Follow this link:
Winter Symposium 2012 - Personalized Medicine Q

12-10-2011 16:47 part 2.

Read the rest here:
Vineyard Personalized Medicine - Lisa Nagy, MD (continued) - Video

10-01-2012 07:19 A talk by Dr. Peter Tonellato (Friday, December 17, 2010)

Read the original post:
Personalized Medicine: An Approach to Optimal Individualized Warfarin Treatment ... (CIBEC'10) - Video

04-01-2012 13:51 Dr. Brian Druker, Director of the OHSU Knight Cancer Institute, shares how what he and his colleagues have learned in the study of Chronic Myelogenous Leukemia (CML) has forwarded a personalized medicine approach - something he believes is simply an extension of compassionate care.

Read more from the original source:
Brian Druker: Compassionate Care and Personalized Medicine - Video

18-11-2011 15:24 David Alberts, MD Cancer Center Director The Arizona Cancer Center Suellen Crano, PhD Patient of David Alberts, MD Survivor of Peritoneal Mesothelioma

Go here to see the original:
Personalized Medicine Success Story - Video

How to spend less on medicine and keep yourself healthy

Read more:
Personalized Medical Care - Video

For decades, cancers have been treated based on how they look under a microscope. We now know that while cancers may look similar, specific abnormalities in the DNA of tumor cells can make each person's cancer respond differently to treatment.

Read more here:
My Health Chat - Personalized Cancer Treatment - Video

Professor Stephen Koslow gives this presentation at the First National Symposium on Translational Psychiatry, 4 -5 April 2011, at The John Curtin School of Medical Research, The Australian National University. Dr. Stephen H

Go here to read the rest:
Professor Stephen Koslow - Personalised medicine - Video

In the latest Matrix Minute, Matrix Group CEO Joanna Pineda interviews Dean Gaalaas, CEO of EdgeBio, on the power of DNA sequencing in personalized medicine. In this day and age when caring for one's health is a high priority, Gaalaas talks about how DNA sequencing can help individuals take preventive measures to maintain healthy lifestyles to helping doctors recommend regiments to patients diagnosed with diseases and other ailments.

View post:
The Power of DNA Sequencing in Personalized Medicine - Video

The University of Louisville overviews the intersection of computer science and biology in its research towards personalized medicine. The University's use of a visualization wall to view and study results generated by the Dell HPC cluster is very interesting and is helping make great strides in the University's studies.

See original here:
University of Louisville: Realizing Personalized Medicine with Dell HPC - Video

Anna D.

The rest is here:
Vision for Personalized Medicine Future of Industry and Region - Video

Visit us at envita.com The only medical centers of its kind, Envita offers an extensive array of advanced natural and conventional treatments from all over the world. Personalized medicine at the highest level and changing outcomes sums up Envita Medical Centers. Envita's PPMR the future of medicine offered today

See the original post here:
Envita's Personalized Medicine that matters for Cancer and Chronic disease - Video

See the rest here:
GPEC: Full Personalized Medicine - Video

Founder Celebration 2011 - At the Dawn of Personalized Medicine: Transforming The Diagnosis

View post:
2011 Foundation Forum: At the Dawn of Personalized Medicine - Video

See more here:
personalized medicine day 1 - Video

Jamie Heywood, chairman and co-founder of PatientsLikeMe, is a pioneer in online health information. He has invited thousands of patients to answer questions online about their personal health knowing the data is aggregated for drug companies and researchers

Read more from the original source:
Patients as Partners in Personalized Medicine - Video

Dr.

More here:
Personalized Medicine for Lung Cancer - Video